“There is no admission of liability, and we remain steadfast that the claims raised in the litigation contradict years of scientific data and the U.S. Food and Drug Administration’s repeated confirmation of Xarelto’s safety and efficacy.” These are the words a Janssen Pharmaceuticals spokeswoman emailed the Associated Press in an effort to take the sting out of the fact that the company, along with Bayer, had just read more.... -->
continue reading...
It was the first loss handed to Bayer and Johnson & Johnson’s Janssen Pharmaceuticals over Xarelto. And when it was all over, an Indiana woman walked away with a verdict awarding her nearly $28 million. Or, so she thought.
Lynn Hartman’s Xarelto lawsuit verdict was notable not only for the size of the award but also because it was the first time Bayer and Johnson & Johnson had ...
continue reading...Philadelphia is known for many things. Our sports teams, foods, drinks, and landmarks are household terms from coast to coast. However, the Philadelphia Court of Common Pleas has a reputation of its own, and that reputation has earned it a place on a list as simultaneously adored and hated as the phrase “Fly Eagles Fly.”
This year marked the return of Philadelphia to the American ...
continue reading...Johnson & Johnson and Bayer AG had been on a roll with Xarelto lawsuits. Three previous Xarelto verdicts had gone in their favor as juries in bellwether cases in Louisiana and Mississippi found no issues concerning Xarelto’s safety while also finding that the drug’s manufacturers adequately warned physicians and the public over the possible dangers of taking the popular blood thinner.
A Philadelphia jury was ...
continue reading...Xarelto Bellwether Cases Inch Closer to Court Dates
Posted June 1, 2017 in Product News and Recalls | xarelto
In 2011, the FDA approved a drug that many hoped would be the first step forward in blood thinning medication since Coumadin’s debut in the 1960s: Xarelto.
Created by Johnson & Johnson and Bayer, Xarelto has been responsible for over $3.2 billion in profits for its manufacturers and developers. It has also become Bayer’s top-selling medication ever. Yet despite its successes on paper, the reality is that more than 18,000 ...
continue reading...Bellwether Xarelto Bleeding Case Ends With Defense Verdict
Posted May 9, 2017 in Product News and Recalls | xarelto
Few drugs have taken the market by storm like Xarelto. Developed as an improvement over Coumadin; the ‘standard’ of blood thinning medications since the 1960s, Xarelto has seen billions of dollars in sales growth since its release in 2011. In fact, Xarelto sales more than doubled in the four-year span between 2013 and 2016, topping out at $3.2 billion in 2016. This makes it Bayer’s top-selling medication.
On the ...
continue reading...
